This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
J&J Expects Better Top-Line Growth in 2H: Can It Achieve the Goal?
by Kinjel Shah
JNJ lifts 2025 sales and EPS outlook on strong Q2 results, with new drug launches and MedTech gains fueling momentum.
How Did Skyrizi and Rinvoq Sales Contribute to AbbVie's Q2 Results?
by Sundeep Ganoria
AbbVie's Q2 results show Skyrizi and Rinvoq powering growth, offsetting Humira declines and lifting 2025 sales outlook.
Economy Heating Up on PCE for June
by Mark Vickery
Pre-market and bond yield numbers appear to be in reaction to this morning's economic posts.
TEVA Q2 Earnings Beat, Revenues Miss on Lower Generics Sales
by Zacks Equity Research
TEVA tops Q2 earnings expectations as branded drugs shine, but revenues slip on weak generics and Japan exit.
AbbVie Beats on Q2 Earnings & Sales, Stock Up on Raised '25 EPS View
by Zacks Equity Research
ABBV tops Q2 forecasts and lifts 2025 EPS outlook as Rinvoq and Skyrizi drive growth amid Humira's decline.
PCE Comes in Warmer Than Expected
by Zacks Equity Research
PCE Comes in Warmer Than Expected.
AbbVie (ABBV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
AbbVie (ABBV) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
AbbVie (ABBV) delivered earnings and revenue surprises of +2.77% and +2.35%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Pfizer (PFE) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Pfizer (PFE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pre-Q2 Earnings: Is AbbVie Stock a Portfolio Must-Have?
by Sundeep Ganoria
ABBV's Q2 results are likely to hinge on Skyrizi and Rinvoq growth as Humira declines, with 2025 set for a strong revenue rebound.
Will These 5 Pharma/Biotech Bigwigs Surpass Q2 Earnings Forecasts?
by Ahan Chakraborty
Let's look at five biotech and drug companies, MRK, AZN, BMY, ABBV and MRNA, slated to release their second-quarter 2025 results this week.
AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
J&J Innovative Medicine Unit Shines Again in Q2: Will This Continue?
by Kinjel Shah
JNJ's Innovative Medicine unit posts solid Q2 growth despite Stelara's LOE, powered by Darzalex, Tremfya, Erleada and new drugs.
AbbVie (ABBV) Outperforms Broader Market: What You Need to Know
by Zacks Equity Research
AbbVie (ABBV) reached $187.12 at the closing of the latest trading day, reflecting a +1.23% change compared to its last close.
Top Research Reports for NVIDIA, Amazon.com & Meta Platforms
by Mark Vickery
NVIDIA, Amazon.com, and Meta Platforms stand out in Zacks' latest picks, backed by AI growth, AWS strength, and global user gains.
How Will AbbVie's Neuroscience Franchise Perform in Q2 Earnings?
by Sundeep Ganoria
ABBV's neuroscience sales are projected to jump 15% in Q2, driven by Botox Therapeutic, Vraylar and oral migraine drug gains.
Betting Big on Cancer: 3 Oncology Stocks Set to Surge in 2025
by Kinjel Shah
J&J, Novartis and Allogene Therapeutics are making bold oncology moves as demand surges for next-generation cancer therapies.
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
AbbVie (ABBV) Surpasses Market Returns: Some Facts Worth Knowing
by Zacks Equity Research
The latest trading day saw AbbVie (ABBV) settling at $190.58, representing a +2.25% change from its previous close.
How Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?
by Sundeep Ganoria
ABBV's oncology sales might have dipped in Q2 as gains from newer drugs face pressure from Imbruvica's ongoing decline.
Here's How to Play AbbVie Stock as it Reaches Golden Cross
by Kinjel Shah
ABBV hits a bullish golden cross as Skyrizi and Rinvoq drive growth, offsetting Humira losses and aesthetic headwinds.
ABBV or BMY: Which Biopharma Giant Has Better Prospects for Now?
by Ekta Bagri
AbbVie edges ahead of Bristol Myers with strong Skyrizi and Rinvoq growth, offsetting Humira declines and portfolio headwinds.
AbbVie (ABBV) Laps the Stock Market: Here's Why
by Zacks Equity Research
AbbVie (ABBV) closed the most recent trading day at $195, moving +2.3% from the previous trading session.